Marinus, Provention take spot in Nasdaq Biotechnology Index

 

• Provention Bio (PRVB +2.2%), Marinus Pharmaceuticals (MRNS -1.5%), Arcutis Biotherapeutics (ARQT +0.2%) and Kamada (KMDA +1.1%) have been added to the Nasdaq Biotechnology Index, effective market open today (Dec 21).
• "Index inclusion recognizes our clinical progress and heightened investor awareness as we remain committed to rapidly advancing our pipeline in rare epilepsies and neuropsychiatric disorders," says Scott Braunstein, M.D., CEO of Marinus Pharmaceuticals.
• In the past one year, stock price return of PRVB, ARQT, and MRNS remains higher to the the iShares NASDAQ Biotechnology Index (NASDAQ:IBB), which tracks the Nasdaq Biotechnology Index. On the other side, KMDA has posted a decline of 9.70% in the same period.
• https://seekingalpha.com/news/3646366-marinus-pharmaceuticals-provention-bio-take-spot-in-nasdaq-biotechnology-index